Hair Experts Report Varying Steroid Techniques for Alopecia
METHODOLOGY:
Researchers surveyed 28 dermatologists with hair expertise using a 77-question REDCap survey.
Participants averaged 17.7 years of experience, with completion of residency between 1985 and 2022.
The response rate was 75% (21 experts completed the survey).
The survey assessed ILC injection techniques across alopecia types, including facial alopecia.
TAKEAWAY:
For nonscarring alopecia, 5 mg/mL was the most common ILC dose (85.7%), followed by 2.5 mg/mL (38.1%); 95.2% of experts injected between 1 and 1.5 mL per session, 95.2% used a 30-gauge needle, and 95.2% injected in a grid pattern.
Most experts (71.4%) employed identical ILC techniques for both scarring and nonscarring alopecia, with 61.9% and 60%, respectively, preferring 6-week treatment intervals. The most common ILC dose for scarring alopecia was 5 mg/mL (60%), followed by 7.5 mg/mL (40%) and 10 mg/mL or more (40%).
For facial alopecia, 80% of experts used a lower concentration of 2.5 mg/mL, and 90% typically performed 3-4 sessions.
For nonscarring alopecia, experts suggested injecting parallel to the direction of hair growth to reduce pain and avoid follicle damage, and for scarring alopecia, they recommended starting with peripheral injections and moving toward the center of the lesion. For facial alopecia, experts recommended shallow injections and avoiding visible vessels to prevent atrophy and bruising.
IN PRACTICE:
'Our findings reveal general agreement amongst experts on the use of ILCs for alopecia; however, variation remains in concentration, injection spacing, and treatment duration, especially for facial and scarring alopecia,' the study authors wrote. Although a Delphi study 'could help standardize' ILC treatment approaches, they added, their results 'provide practical guidance for dermatologists on intralesional corticosteroid techniques for the treatment of various alopecia types.'
SOURCE:
This study was led by Noelle Desir, Department of Dermatology, University of Pennsylvania, Philadelphia, and was published online on June 3 in JAAD International .
LIMITATIONS:
Limitations included the hair expert identification process and potential response bias in the survey.
DISCLOSURES:
This study did not receive any funding. One study author reported serving as a consultant, advisory board member, speaker, and investigator for various pharmaceutical and cosmetic companies, including AbbVie, Arcutis Biotherapeutics, Pfizer, and L'Oréal, and also reported receiving royalties from McGraw Hill. Another author reported serving as an advisory board member for Beiersdorf. The remaining authors reported no conflicts of interest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
(Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. Trump Awards $1.26 Billion Contract to Build Biggest Immigrant Detention Center in US The High Costs of Trump's 'Big Beautiful' New Car Loan Deduction Can This Bridge Ease the Troubled US-Canadian Relationship? Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Trump Administration Sues NYC Over Sanctuary City Policy On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. (Updates with statement from FDA in sixth and seventh paragraphs.) Burning Man Is Burning Through Cash Confessions of a Laptop Farmer: How an American Helped North Korea's Wild Remote Worker Scheme It's Not Just Tokyo and Kyoto: Tourists Descend on Rural Japan Elon Musk's Empire Is Creaking Under the Strain of Elon Musk A Rebel Army Is Building a Rare-Earth Empire on China's Border ©2025 Bloomberg L.P. Sign in to access your portfolio
Yahoo
7 minutes ago
- Yahoo
Meta names ChatGPT co-creator as chief scientist of Superintelligence Lab
By Echo Wang NEW YORK (Reuters) -Meta Platforms has appointed Shengjia Zhao, co-creator of ChatGPT, as chief scientist of its Superintelligence Lab, CEO Mark Zuckerberg said on Friday, as the company accelerates its push into advanced AI. "In this role, Shengjia will set the research agenda and scientific direction for our new lab working directly with me and Alex," Zuckerberg wrote in a Threads post, referring to Meta's Chief AI Officer Alexandr Wang, who Zuckerberg hired from startup Scale AI when Meta took a big stake in it. Zhao, a former research scientist at OpenAI, co-created ChatGPT, GPT-4 and several of OpenAI's mini models, including 4.1 and o3. He is among several researchers who have moved from OpenAI to Meta in recent weeks, part of a broader talent arms race as Zuckerberg aggressively hires from rivals to close the gap in advanced AI. Meta has been offering some of Silicon Valley's most lucrative pay packages and striking startup deals to attract top researchers, a strategy that follows the underwhelming performance of its Llama 4 model. Meta launched the Superintelligence Lab recently to consolidate work on its Llama models and long‑term artificial general intelligence ambitions. Zhao is a co-founder of the lab, according to the Threads post, which operates separately from FAIR, Meta's established AI research division led by deep learning pioneer Yann LeCun. Zuckerberg has said Meta aims to build 'full general intelligence' and release its work as open source — a strategy that has drawn both praise and concern within the AI community.
CBS News
9 minutes ago
- CBS News
Boston renter says mice, bed bug problem has gotten worse, warns against used furniture
Boston's rodent and bed bug problem may be getting worse. A man who rents on Mission Hill says his landlord has been trying to get rid of the pests for months, and he's not alone. Fritz, who wanted to remain anonymous, said he's been experiencing bed bugs and mice at his apartment on Hillside Street on Mission Hill. He's been living there for almost a year. He started noticing mice in the building about six months ago. "We've been seeing four or five that we've caught then we've put everything in jars that mice can't get to, but we are still seeing mice," Fritz said. "Then we also had an incident with bed bugs." Fritz said after multiple exterminator visits, the problem is not going away in their unit. "There were droppings all over the pantry, a little bit on the floor," Fritz said. "It also just made it kind of gross to go cook in the kitchen when there may be mice droppings. We would clean it up and then a couple days later they obviously came back. Just makes it really tough." "We understand that neighborhoods with high rates of tenant turnover are particularly vulnerable to bed bug infestations-especially when used furniture is brought into homes or when residents attempt do-it-yourself treatments," Boston Inspectional Services said. "We strongly encourage anyone experiencing an infestation to immediately notify their landlord so that prompt and proper treatment can begin." Which is something Fritz has done on multiple occasions. "I think the message the landlord is sending is that he's doing everything he can. But from our perspective every day we are still seeing mice and bed bugs," Fritz said. "Makes it tough to stay there especially with the high rent prices." He also says he's been spending less time at his apartment because the issue hasn't been resolved. "I have heard that it's gotten worse," Fritz said. "I did speak with Terminix, and they said that they've seen an uptick in especially the Boston area, specifically with college students." Fritz, who just graduated college last year, warns college students who are getting ready to move back into their apartments soon to avoid used furniture. "It may seem like a good deal, a $50 couch but definitely worth it to just go and buy a new one in my opinion," Fritz said. "Or if you are getting used furniture, definitely make sure you are at least checking it, making sure there are no bed bugs on it, because you will be paying a lot more in exterminator fees than you will be in just buying the new property."
